安徽丰原药业股份有限公司 关于控股股东及其一致行动人拟协议转让 公司部分股份暨权益变动的提示性公告 公司控股股东及其一致行动人和受让方保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 股票简称：丰原药业 股票代码：000153 公告编号：2025-025 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 1、安徽丰原药业股份有限公司（以下简称"公司"或"上市公司"）控股股东安徽丰原集团有 限公司（以下简称"丰原集团"）及其一致行动人马鞍山丰原企业管理有限公司（简称"马鞍山丰 原"）拟通过协议转让方式，向海南贵和达毅投资合伙企业（有限合伙）（以下简称"贵和达毅"） 转让其持有的公司股份合计 23,698,554 股，占公司总股本的 5. 10%（以下简称"本次交易"）。 2、本次交易不涉及要约收购，不涉及关联交易。 3、本次交易不会导致公司控制权发生变化，不会对公司治理结构及持续经营产生重大影响。 4、本次交易转让双方将严格遵守《上市公司股东减持股份管理暂行办法》《深圳证券交易所 上市公司自律监管指引第 18 号—— ...

安徽丰原药业股份有限公司 简式权益变动报告书 上市公司名称：安徽丰原药业股份有限公司 股票上市地点：深圳证券交易所 股票简称：丰原药业 股票代码：000153 信息披露义务人一：安徽丰原集团有限公司 住所：安徽省蚌埠市禹会区胜利西路777号 通讯地址：安徽省蚌埠市禹会区胜利西路777号 信息披露义务人二：马鞍山丰原企业管理有限公司 住所：安徽省马鞍山经济技术开发区梅山路1503号 通讯地址：安徽省蚌埠市禹会区胜利西路777号 股权变动性质：股份减少（协议转让） 签署日期：2025 年08月11日 1 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15号——权益变动报告书》及相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定， 本报告书已全面披露信息披露义务人在安徽丰原药业股份有限公司拥有权益的 股份变动情况。截至本报告书 ...

安徽丰原药业股份有限公司 简式权益变动报告书 上市公司名称：安徽丰原药业股份有限公司 上市地点：深圳证券交易所 股票简称：丰原药业 股票代码：000153 信息披露义务人：海南贵和达毅投资合伙企业（有限合伙） 主要经营场所：浙江省杭州市滨江区科技馆街1058号24楼 股份变动性质：股份增加（协议转让） 签署日期：2025年8月11日 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15号——权益变动报告书》及相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定， 本报告书已全面披露信息披露义务人在安徽丰原药业股份有限公司拥有权益的 股份变动情况。截至本报告书签署之日，除本报告书披露的信息外，上述信息披 露义务人没有通过任何其他方式增加或减少其在丰原药业中拥有权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的。除本信 ...

Core Viewpoint - Anhui Fengyuan Pharmaceutical Co., Ltd. announced the transfer of 23,698,554 shares, representing 5.10% of the total share capital, from its controlling shareholder Fengyuan Group to Hainan Guihe Dayi at a price of 6.72 CNY per share, totaling 159 million CNY [1] Group 1 - The transaction involves a share transfer that does not lead to a change in company control or affect governance and operations [1] - The buyer has committed to not reducing their stake within 18 months after the transfer [1] - The transaction is subject to compliance review by the Shenzhen Stock Exchange, introducing uncertainty regarding its final completion [1]

金融界消息 截至2025年8月5日收盘，丰原药业（000153）报收于7.38元，上涨0.54%，换手率6.45%， 成交量29.23万手，成交金额2.16亿元。 资金流向方面，今日主力资金净流出1553.27万元，占比成交额7.2%。其中，超大单净流出193.46万 元、占成交额0.9%，大单净流出1359.81万元、占成交额6.3%，中单净流出流出467.59万元、占成交额 2.17%，小单净流入2020.85万元、占成交额9.36%。 丰原药业最新一期业绩显示，截至2025一季报，公司营业总收入9.41亿元、同比减少16.05%，归属净利 润3802.08万元，同比减少19.12%，扣非净利润3352.73万元，同比减少19.55%，流动比率0.933、速动比 率0.657、资产负债率56.43%。 天眼查商业履历信息显示，安徽丰原药业股份有限公司，成立于1997年，位于芜湖市，是一家以从事医 药制造业为主的企业。企业注册资本46477.3722万人民币，实缴资本3670.6137万人民币。公司法定代表 人为汝添乐。 通过天眼查大数据分析，安徽丰原药业股份有限公司共对外投资了20家企业，参与招投标项目2 ...

Group 1 - The stock price of Fengyuan Pharmaceutical closed at 7.50 yuan on July 29, 2025, down 1.45% from the previous trading day, with a trading range of 8.94% [1] - The company is primarily engaged in the research, production, and sales of chemical raw materials and formulations, covering various therapeutic areas including antipyretic analgesics, antibiotics, and vitamins [1] - As a key enterprise in the pharmaceutical industry of Anhui Province, Fengyuan Pharmaceutical's business involves multiple segments including raw materials, formulations, and pharmaceutical commerce [1] Group 2 - On July 29, the stock experienced significant volatility, with a drop of over 2% within 5 minutes around 9:35 AM, followed by a rebound of over 2% shortly after at 9:41 AM, indicating active market trading [1] - The net outflow of main funds was 21.79 million yuan, accounting for 0.64% of the circulating market value, suggesting a certain degree of capital withdrawal [1]

通过天眼查大数据分析，安徽丰原药业股份有限公司共对外投资了20家企业，参与招投标项目237次， 知识产权方面有商标信息79条，专利信息51条，此外企业还拥有行政许可328个。 来源：金融界 丰原药业最新一期业绩显示，截至2025一季报，公司营业总收入9.41亿元、同比减少16.05%，归属净利 润3802.08万元，同比减少19.12%，扣非净利润3352.73万元，同比减少19.55%，流动比率0.933、速动比 率0.657、资产负债率56.43%。 天眼查商业履历信息显示，安徽丰原药业股份有限公司，成立于1997年，位于芜湖市，是一家以从事医 药制造业为主的企业。企业注册资本46477.3722万人民币，实缴资本3670.6137万人民币。公司法定代表 人为汝添乐。 金融界消息 截至2025年7月29日收盘，丰原药业（000153）报收于7.5元，下跌1.45%，换手率24.86%， 成交量112.58万手，成交金额8.65亿元。 资金流向方面，今日主力资金净流出2178.83万元，占比成交额2.52%。其中，超大单净流出6119.80万 元、占成交额7.08%，大单净流入3940.97万元、占成交额4 ...

Group 1 - The vitamin sector has seen a rise of 2.34%, ranking 9th among concept sectors, with 62 stocks increasing in value [1][2] - Notable gainers include Nonnawell, Fengyuan Pharmaceutical, and Nengte Technology, which reached the daily limit, while Minsheng Health, Zhenhua Co., and Erkang Pharmaceutical also showed significant increases of 8.75%, 7.15%, and 6.69% respectively [1][2] - The sector experienced a net inflow of 5.92 billion yuan from main funds, with 43 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan in net inflow [2][3] Group 2 - The top stocks by net inflow include Nonnawell with 925.69 million yuan, followed by Fengyuan Pharmaceutical with 884.21 million yuan, and Zhongsheng Pharmaceutical with 728.46 million yuan [2][3] - The net inflow ratios for Fengyuan Pharmaceutical, Nengte Technology, and Huate Dain are 24.78%, 19.08%, and 14.28% respectively, indicating strong investor interest [3] - Stocks such as Dongbao Biological, Huate Dain, and Huaheng Biological experienced declines of 3.71%, 2.04%, and 0.91% respectively, highlighting some volatility within the sector [1][5]

Core Viewpoint - The concept of generic drug consistency evaluation has seen a rise of 2.73%, ranking fifth among concept sectors, with significant inflows of capital into various stocks within this sector [1][2]. Group 1: Market Performance - As of July 1, the generic drug consistency evaluation concept experienced a 2.73% increase, with 120 stocks rising, including top performers like Fengyuan Pharmaceutical, Guizhou Bailing, and Anglikang, which hit the daily limit [1]. - The leading gainers in this sector included Yuekang Pharmaceutical (up 15.55%), Yipinhong (up 14.72%), and Hongri Pharmaceutical (up 8.13%) [1][2]. - Conversely, the stocks with the largest declines were Yiming Pharmaceutical, Yongtai Technology, and *ST Suwu, which fell by 2.16%, 1.71%, and 0.79% respectively [1]. Group 2: Capital Inflows - The generic drug consistency evaluation sector attracted a net inflow of 829 million yuan, with 74 stocks receiving capital inflows, and 13 stocks seeing over 50 million yuan in net inflows [2]. - The stock with the highest net inflow was Yipinhong, which saw 168 million yuan, followed by Guizhou Bailing and Huahai Pharmaceutical with net inflows of 158 million yuan and 135 million yuan respectively [2][3]. - The top three stocks by net inflow ratio were Fengyuan Pharmaceutical (24.78%), Guizhou Bailing (17.80%), and Huahai Pharmaceutical (14.87%) [3]. Group 3: Stock Performance Metrics - Yipinhong had a daily increase of 14.72% with a turnover rate of 5.65% and a net capital flow of approximately 168 million yuan [3]. - Guizhou Bailing increased by 10.04% with a turnover rate of 13.11% and a net capital flow of about 158 million yuan [3]. - Huahai Pharmaceutical rose by 5.74% with a turnover rate of 3.26% and a net capital flow of around 135 million yuan [3].

Core Viewpoint - Anhui Fengyuan Pharmaceutical Co., Ltd. has announced its profit distribution plan for the year 2024, which includes a cash dividend of 1 RMB per 10 shares, approved by the shareholders' meeting held on May 6, 2025 [1][2]. Summary by Sections Profit Distribution Plan - The company plans to distribute a cash dividend of 1 RMB (including tax) for every 10 shares based on a total share capital of 464,773,722 shares as of December 31, 2024 [1]. Implementation of the Distribution - The cash dividend distribution will be executed as follows: for every 10 shares, a cash dividend of 1 RMB will be paid to all shareholders. For overseas institutions and certain individual shareholders, the dividend will be 0.9 RMB per 10 shares due to tax considerations [1]. - The tax treatment for individual shareholders varies based on the holding period of the shares, with specific tax rates applied for different durations [1]. Key Dates - The record date for the distribution is set for May 29, 2025, and the ex-dividend date is May 30, 2025 [1][2]. Distribution Recipients - The recipients of the dividend will be all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [2]. Consultation Information - The company has provided contact details for inquiries regarding the dividend distribution, including a contact person and phone numbers [2].